Pipamperone
From Wikipedia, the free encyclopedia
 |
|
|
Pipamperone
|
|
| Systematic (IUPAC) name | |
| 1-[4-(4-fluorophenyl)-4-oxo-butyl]-4-(1-piperidyl)piperidine-4-carboxamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | C21H30FN3O2 |
| Mol. mass | 375.480 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Pipamperone is an antipsychotic drug (a butyrophenone derivative) used in the treatment of schizophrenia. Pipamperone is known to the general public under the marketed brand name Dipiperon.
Pipamperone was discovered at Janssen Pharmaceutica in 1960.
[edit] References
- Fouks, Mathis, Gilbert, Ferragu, Houssait, Lerno, Treatment of character disorders with a new butyrophenone: R. 3345 or pipamperone, Ann Med Psychol (Paris). 1966 Dec;124(5):677-81.
- Deberdt R., Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large-scale multicentre evaluation, Acta Psychiatr Belg. 1976 Jan-Feb;76(1):157-66.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
